Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Shenzhen Edge Medical (精锋医疗) IPO: Well-Timed Launch Supports Valuation

Shenzhen Edge Medical (精锋医疗) Pre-IPO: Fast Follower, Competition Is Intense

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Shenzhen Edge Medical / Equity Capital Markets

<ul>
<li>Shenzhen Edge Medical raised HKD 1199m (USD 154m) from its global offering and will list on the Hong Kong Stock Exchange on Thursday January 8th, 2026.</li>
<li>In our previous note, we looked at the company's fundamentals, and the valuation.</li>
<li>In this note, we provide an update for the IPO before trading debut.</li>
</ul>


Shenzhen Edge Medical raised HKD 1199m (USD 154m) from its global offering and will list on the Hong Kong Stock Exchange on Thursday January 8th, 2026.
In our previous note, we looked at the company's fundamentals, and the valuation.
In this note, we provide an update for the IPO before trading debut.


Shenzhen Edge Medical (精锋医疗) IPO Trading